HMOX1 and metabolic dysfunction-associated steatotic liver disease: EETs have been shown to improve non-alcoholic fatty liver disease (NAFLD) in mice by increasing PGC-1α-HO-1, reducing fatty acid accumulation and fibrosis, and increasing insulin receptor phosphorylation [43,44].